Colorectal cancer (CRC) is a formidable health challenge, ranking as the second leading cause of cancer-related deaths in the United States. This disease disproportionately affects individuals who receive care in under-resourced healthcare environments, highlighting significant health disparities that demand urgent attention. Early detection through screening remains paramount, as it markedly improves treatment outcomes and survival rates. Despite the availability of several effective screening modalities, underutilization persists in medically underserved populations, especially those attending community health centers (CHCs).
In an ambitious effort to bridge this gap, researchers affiliated with Mass General Brigham and UCLA Health undertook a large-scale investigation aimed at increasing CRC screening uptake among patients engaged in CHCs situated in Boston and Los Angeles. The study focused on mailed outreach approaches involving two stool-based screening tests: the traditional fecal immunochemical test (FIT) and a novel FIT-DNA test, which integrates DNA mutation analysis with hemoglobin detection. These noninvasive, at-home tests enable convenient screening outside conventional clinical settings.
The randomized clinical trial encompassed over 5,000 adults aged 45 to 75 years who were clinically due for CRC screening. The patient population was predominantly Hispanic (75%), with half enrolled in Medicaid, underscoring the socioeconomically vulnerable nature of this cohort. Participants were randomly assigned to receive either the classic FIT kit with automated bilingual text reminders or the more recently developed FIT-DNA kit, which includes a patient assistance program managed by the test manufacturer. This program facilitates outreach, education, and logistical support aimed at enhancing completion rates.
Findings revealed a notable difference in screening completion between the two groups at the 90-day mark. Approximately 28% of individuals receiving the FIT-DNA kits returned completed tests, a statistically significant improvement over the 23% completion observed among those sent the FIT kits with automated text reminders. Investigators surmise that this disparity may stem from the comprehensive outreach and patient support baked into the FIT-DNA distribution system, coupled with the less burdensome screening frequency of once every three years, compared to annual FIT testing.
Complementing these results, a parallel study conducted at a tribal healthcare site in South Dakota further demonstrated an increase in CRC screening participation linked to the FIT-DNA test distribution, a finding critical given the elevated CRC incidence and historically low screening rates in Native American populations. These studies collectively emphasize the necessity of tailored interventions adapted to the unique demographics and resource constraints of underserved communities.
Notwithstanding the encouraging progress in test completion, the research underscores a significant bottleneck in follow-up diagnostic colonoscopy after stool test abnormalities. In both groups, colonoscopy completion rates hovered at a suboptimal 36%, despite proactive phone outreach designed to educate patients about the importance of diagnostic follow-up and to facilitate scheduling. This attrition in the diagnostic cascade was particularly pronounced in Los Angeles relative to Boston, possibly reflecting regional disparities in healthcare infrastructure or insurance coverage complexities.
The implications of these results are multifaceted. While noninvasive stool-based tests with enhanced support systems can markedly elevate initial screening engagement, the critical step of diagnostic colonoscopy following positive screens remains a barrier that could undermine overall screening efficacy. The shortage of colonoscopy completion threatens the early identification of CRC and diminishes the potential survival benefits conferred by screening programs.
The study’s lead author, Dr. Jennifer Haas of Mass General Brigham’s Division of Internal Medicine, highlights the intrinsic challenges faced by CHCs, which serve as principal providers for under- or uninsured populations and operate within resource-limited environments. She reinforces that effective CRC prevention hinges not only on distributing screening tests but also on orchestrating systematic, patient-centered interventions that address obstacles faced by both healthcare providers and patients.
Moreover, the research team, part of the Stand Up To Cancer (SU2C) Colorectal Cancer Health Equity Dream Team, integrates multidisciplinary expertise spanning researchers, patient advocates, and clinicians to tackle systemic inequities in CRC prevention. Their mission is to establish equitable access to evidence-based screening while ensuring novel interventions translate into real-world benefits for medically underserved populations.
From a technical standpoint, the FIT-DNA test’s capacity to detect neoplastic DNA in addition to occult blood enhances its clinical sensitivity, potentially identifying patients with early-stage cancers or high-risk precancerous polyps that might be missed by FIT alone. Its recommended three-year screening interval not only reduces patient burden but may also enhance adherence. The manufacturer-administered outreach model simplifies implementation for CHCs, offsetting administrative and financial barriers that often impede traditional test mailing and follow-up procedures.
Nonetheless, this promising innovation does not obviate challenges in downstream care delivery. Barriers to colonoscopy completion—ranging from limited procedure availability, patient transportation issues, financial constraints, to inadequate insurance coverage—require targeted health system reforms and community-level support to ensure patients derive full benefit from initial screening efforts.
Collectively, these findings illuminate a comprehensive picture of colorectal cancer screening dynamics in under-resourced clinical settings. They suggest that while newer stool-based tests coupled with robust patient assistance programs can meaningfully enhance screening test completion rates, substantial work remains to improve follow-up diagnostic care. Bridging these gaps is imperative to curtail CRC mortality and achieve health equity in cancer prevention.
As Dr. Haas articulates, “The best screening test is ultimately the one that patients complete.” Therefore, strategic investment in tailored outreach programs, patient education, and systemic capacity building are indispensable components to optimize CRC screening outcomes. These initiatives must be thoughtfully designed to respect cultural, linguistic, and socioeconomic factors that influence patient engagement in vulnerable populations.
This study represents a pivotal advancement in cancer prevention research, demonstrating the tangible impact of integrating innovative testing technologies with patient-centric support in real-world healthcare settings. It lays the groundwork for future efforts to scale effective interventions and dismantle the multifactorial barriers impeding colorectal cancer screening in underserved communities across the nation.
Subject of Research: People
Article Title: Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial
News Publication Date: 27-Apr-2026
Web References:
https://jamanetwork.com/journals/jamainternmed/fullarticle/10.1001/jamainternmed.2026.1170
References:
May FP et al. “Mailed Outreach for Colorectal Cancer Screening in Community Health Centers.” JAMA Internal Medicine., DOI: 10.1001/jamainternmed.2026.1170
Keywords:
Colorectal cancer, cancer screening, health disparity, health care delivery, fecal immunochemical test, FIT-DNA, community health centers, colonoscopy, cancer prevention, health equity
